Pune, March 20, 2025 (GLOBE NEWSWIRE) — Liquid Biopsy Market Size & Growth Analysis:
According to SNS Insider, the global liquid biopsy market, which was valued at USD 7.20 billion in 2023, is anticipated to expand to USD 21.78 billion by 2032. This projection reflects a compound annual growth rate of 13.11% over the forecast period from 2024 to 2032.
Liquid biopsy, a minimally invasive diagnostic method, identifies circulating tumor cells (CTCs), cell-free nucleic acids, and exosomes in body fluids and provides a holistic genomic portrait of tumors without requiring conventional tissue biopsies. This method enables early cancer diagnosis, monitoring of treatment response, and detection of therapeutic targets, thus improving personalized medicine approaches. The rise in cancer cases across the world, along with the change towards non-surgical diagnostic methods, has driven the use of liquid biopsy technologies.
Advances in technology, like the combination of next-generation sequencing (NGS) and increases in assay specificity and sensitivity, have further enhanced the market. These technologies provide for the detection of low-prevalence genetic mutations and continuous real-time tumor dynamics monitoring, which results in more effective clinical decisions and enhanced patient outcomes. Moreover, increased awareness by healthcare providers and patients regarding the advantages of liquid biopsies, such as decreased procedural complications and quicker diagnostic times, have further fueled the market.
Get a Sample Report of Liquid Biopsy Market@ https://www.snsinsider.com/sample-request/5543
Key Liquid Biopsy Companies Profiled
- ANGLE plc – PARSORTIX
- Oncimmune Holdings PLC – ImmunoINSIGHT
- Guardant Health – Guardant360
- Myriad Genetics, Inc. – myChoice CDx
- Biocept, Inc. – Target Selector
- Lucence Health Inc. – LiquidHALLMARK
- Freenome Holdings, Inc. – Freenome Liquid Biopsy Platform
- F. Hoffmann-La Roche Ltd. – Cobas EGFR Mutation Test v2
- QIAGEN – QIAseq Targeted DNA Panels
- Illumina, Inc. – NextSeq and MiSeq Systems
- Thermo Fisher Scientific, Inc. – Oncomine Target Test
- Epigenomics AG – Epi proColon
- Natera, Inc. – Signatera
Liquid Biopsy Market Report Scope
| Report Attributes | Details |
| Market Size in 2023 | US$ 7.20 billion |
| Market Size by 2032 | US$ 21.78 billion |
| CAGR | CAGR of 13.11% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Key Regional Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
Segment Analysis
By Product:
In 2023, the market of instruments dominated the liquid biopsy market with a share of 47.1%. This is due to the vital role played by sophisticated instruments in conducting accurate and reliable liquid biopsy tests. The instruments are very important for the detection and analysis of circulating biomarkers accurately, thus ensuring that diagnostic procedures are effective.
On the other hand, the kits and reagents segment is expected to grow at the highest rate in the forecast period. This is owing to the rise in demand for ready-to-use consumables that simplify workflow efficiency and save time in sample processing. The convenience and standardization provided by the kits and reagents render them essential in both clinical and research environments, hence driving their accelerated adoption.
By Technology:
The segment of multi-gene parallel analysis, including next-generation sequencing (NGS) technologies, dominated the liquid biopsy market in 2023 and maintained a high revenue share of 76.1%. NGS facilitates the concurrent analysis of numerous genetic mutations at once, delivering complete genomic information that is extremely useful for tailoring cancer treatment plans. Its sensitivity and specificity in identifying an extensive range of genetic alterations have established it as a technology of choice within the liquid biopsy market.
Conversely, the single-gene analysis segment, specifically polymerase chain reaction (PCR) microarrays, is expected to see strong growth in the forecast period. PCR microarrays provide an inexpensive and efficient method for the detection of certain genetic mutations and are thus made available for clinical use on a routine basis. Their ease of use, along with continuous improvement that increases their accuracy and throughput, is driving their increasing popularity in different healthcare environments.
Need Any Customization Research on Liquid Biopsy Market, Enquire Now@ https://www.snsinsider.com/enquiry/5543
Liquid Biopsy Market Segmentation
By Product
- Instruments
- Consumables Kits and Reagents
- Software and Services
By Technology
- Multi-gene-parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)
- By Sample Type
- Blood Sample
- Others
By Biomarker
- Circulating Tumor Cells (CTCs)
- Circulating Nucleic Acids
- Exosomes/ Microvesicles
- Circulating Proteins
By Application
- Cancer
- Reproductive Health
- Others
By Clinical Application
- Therapy Selection
- Treatment Monitoring
- Early Cancer Screening
- Recurrence Monitoring
- Others
By End-use
- Hospitals and Laboratories
- Specialty Clinics
- Academic and Research Centers
- Others
Regional Analysis
North America held the highest market share of liquid biopsy in 2023, with a share of 52.3%. This dominance stems from the prevalent incidence of cancer, fast-paced technological breakthroughs, and heavy government support for cancer diagnosis and research. The concentration of many biotechnology firms working on sophisticated tests also strengthens the market in this region. Groups like the American Society of Clinical Oncology (ASCO) are proactively endorsing the use of liquid biopsy technologies, thus increasing their uptake and incorporation into practice.
The Asia-Pacific region is also expected to grow at the highest rate in the forecast period. The reasons behind this rapid growth are improving healthcare reforms, a huge aging population, and rising investments in healthcare infrastructure. The high incidence of cancer in China and India, combined with government initiatives that provide free screening programs for several cancers, will fuel the need for liquid biopsy tests. Government, institute, and company collaborations for the supply and distribution of such tests also increase market growth within this region.
Recent Developments
- January 2025: Oxford Cancer Analytics secured USD 11 million in Series A funding to advance early lung cancer detection and facilitate curative treatments. Additionally, Dr. Heinrich Roder, a specialist in lung cancer proteomics liquid biopsy, has been appointed as Senior Vice President of Research and Development at OXcan.
- January 2025: Mayo Clinic Laboratories partnered with oncology diagnostics company Lucence to broaden global access to Lucence’s LiquidHallmark liquid biopsy technology. This collaboration will allow Mayo Clinic Laboratories to offer Lucence’s liquid biopsy solutions to international markets.
Buy a Single-User PDF of Liquid Biopsy Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/5543
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Liquid Biopsy Market by Product
8. Liquid Biopsy Market by Technology
9. Liquid Biopsy Market by Sample Type
10. Liquid Biopsy Market by Biomarker
11. Liquid Biopsy Market by Application
12. Liquid Biopsy Market by Clinical Application
13. Liquid Biopsy Market by End-use
14. Regional Analysis
15. Company Profiles
16. Use Cases and Best Practices
17. Conclusion
Access Complete Report Details of Liquid Biopsy Market Analysis & Outlook 2024-2032@ https://www.snsinsider.com/reports/liquid-biopsy-market-5543
[For more information or need any customization research mail us at info@snsinsider.com]
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
